Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis? by Gioia, S. et al.
W J H World Journal ofHepatology
Submit a Manuscript: https://www.f6publishing.com World J Hepatol  2019 August 27; 11(8): 613-618
DOI: 10.4254/wjh.v11.i8.613 ISSN 1948-5182 (online)
OPINION REVIEW
Is porto sinusoidal vascular disease to be actively searched in
patients with portal vein thrombosis?
Stefania Gioia, Silvia Nardelli, Lorenzo Ridola, Giulia d’Amati, Oliviero Riggio
ORCID number: Stefania Gioia
(0000-0002-3940-4390); Silvia
Nardelli (0000-0002-7038-9539);
Lorenzo Ridola
(0000-0002-8596-2609); Giulia
d'Amati (0000-0002-6959-691X);
Oliviero Riggio
(0000-0000-2241-3223).
Author contributions: Gioia S
contributed to study concept and
manuscript preparation; Nardelli S
contributed to manuscript
preparation; Ridola L contributed
to manuscript preparation;
d’Amati G contributed to
manuscript preparation and final
drafting of the manuscript; Riggio
O contributed to study concept,
manuscript preparation, final
drafting of the manuscript, and
study supervision.
Conflict-of-interest statement: No
potential conflicts of interest
relevant to this article were
reported.
Open-Access: This article is an
open-access article which was
selected by an in-house editor and
fully peer-reviewed by external
reviewers. It is distributed in
accordance with the Creative
Commons Attribution Non
Commercial (CC BY-NC 4.0)
license, which permits others to
distribute, remix, adapt, build
upon this work non-commercially,
and license their derivative works
on different terms, provided the
original work is properly cited and
the use is non-commercial. See:
http://creativecommons.org/licen
ses/by-nc/4.0/
Manuscript source: Invited
manuscript
Stefania Gioia, Silvia Nardelli, Lorenzo Ridola, Oliviero Riggio, Dipartimento di Medicina
Traslazionale e di Precisione, “Sapienza” Università di Roma, Roma 00185, Italy
Giulia d’Amati, Dipartimento di Scienze Radiologiche, Oncologiche e Anatomo Patologiche,
“Sapienza” Università di Roma, Roma 00185, Italy
Corresponding author: Stefania Gioia, MD, Dipartimento di Medicina Traslazionale e di
Precisione, “Sapienza” Università di Roma, Viale dell’Università 37, Roma 00185, Italy.
stefania.gioia@uniroma1.it
Telephone: +39-6-49970463
Fax: +39-6-49972006
Abstract
Porto sinusoidal vascular liver disease (PSVD) and portal vein thrombosis (PVT)
are distinct vascular liver diseases characterized, respectively, by an intrahepatic
and a prehepatic obstacle to the flow in the liver portal system. PVT may also
occur as a complication of the natural history of PSVD, especially if a
prothrombotic condition coexists. In other cases, it is associated to local and
systemic pro-thrombotic conditions, even if its cause remains unknown in up to
25% despite an active search. In our opinion, the presence of PSVD should be
suspected in patients with PVT especially in those with PVT “sine causa” and the
active search of this condition should be included in their diagnostic work-out.
However, sometimes the diagnosis of pre-existing PSVD is very hard. Biopsy
cannot be fully discriminant as similar histological data have been described in
both conditions. Liver stiffness may help as it has been shown to be higher in
PSVD than in “pure” PVT, due to the presence of sclerosis in the portal venous
radicles observable in PSVD patients. Nevertheless, comparing liver stiffness
between PVT and PSVD has until now been restricted to very limited series of
patients. In conclusion, even if it is still totally hypothetical, our point of view
may have clinical consequences, especially when deciding to perform a liver
biopsy in patients with a higher liver stiffness and suspending the
anticoagulation in patients with PVT and no detectable prothrombotic factors.
Key words: Porto sinusoidal vascular liver disease; Obliterative portal venopathy; Portal
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thrombosis (PVT) are vascular liver diseases. This review aims to discuss the possibility
that (PSVD) should be suspected in patients with PVT and to analyse the possible
diagnostic tools able to differentiate between these two conditions. Moreover, the review
focuses on the possible and relevant clinical consequences of missing a diagnosis of
PSVD in patients with PVT.
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INTRODUCTION
Porto sinusoidal vascular liver disease (PSVD) is a vascular liver disease characterized
by portal hypertension in the absence of cirrhosis and other causes of liver disease[1].
Contrary to the Eastern World and Developing Countries,  in the Western World
PSVD is considered infrequent. However, a low grade of suspicion can contribute, at
least partially, to the low frequency of PSVD in Western Countries. Indeed, in the last
years, the deepening of the knowledge on PSVD and its clinical presentation led to the
recognition of an increasing number of cases and to the awareness that, in the past,
some patients affected by PSVD were misdiagnosed and classified as affected by
cryptogenic  cirrhosis[2].  Moreover,  it  has  been  recently  shown that  a  number  of
disorders and drugs (Table 1)  are associated with PSVD[1,2],  and this observation
suggests that an active search of signs of portal hypertension in patients affected by
those diseases could lead to the identification of PSVD patients.
Patients with portal vein thrombosis (PVT)
This review aims to discuss the possibility that PSVD should be suspected in patients
with  PVT.  In  fact,  a  particular  relationship  exists  between PSVD and PVT.  In  a
considerable number of patients[3], about 40%, PSVD is associated to prothrombotic
conditions,  including myeloproliferative disorders.  The prothrombotic state may
represent a pathogenic factor leading the occlusion of the small branches of the portal
vein, contributing to the so called obliterative portal venopathy (Figure 1A), which is
considered the primary histological lesion of PSVD[4]. In turn, in patients with PSVD,
the  prothrombotic  state  may  favour,  together  with  the  low  portal  flow,  the
development of an extrahepatic portal vein thrombosis. PVT actually occurs in up to
40% of PSVD patients[5,6], especially if a prothrombotic condition coexists. Whether the
anticoagulant therapy is useful for the prevention of portal vein thrombosis or to
improve the natural history of porto sinusoidal vascular liver disease idiopathic non-
cirrhotic portal hypertension is still unknown[7].
The strong relationship between PSVD, hypercoagulability and incidence of PVT
led to the hypothesis that a subset of patients with acute or chronic PVT could be
affected by a pre-existing, undiagnosed PSVD. Actually, despite an active search[8] of
local  or  systemic  predisposing  conditions  (Table  2),  the  cause  of  PVT  is  not
recognizable in up to 25% of the patients. Moreover, in patients in whom a PVT is
diagnosed, the evidence of a prothrombotic state usually leads to the diagnosis of a
PVT secondary to that condition without taking into consideration the possibility of a
pre-existing and undiagnosed PSVD. The possibility of missing a diagnosis of PSVD
in a patient with PVT, especially if acute, may have relevant clinical consequences.
Unfortunately, the distinction between these two conditions is not so easy and well
defined, and the usefulness of liver biopsy to establish a differential diagnosis is
questionable.  In  fact,  while  liver  biopsy  is  adequate  to  exclude  the  presence  of
cirrhosis in patients with portal hypertension, the specific diagnostic features of PSVD
are much more difficult to recognise[2]. More to the point, the histological distinction
between the modification of the liver structure occurring in patients with PSVD (an
intrahepatic cause of low portal perfusion) or PVT (in which the low portal perfusion
is  due  to  extrahepatic  obstruction)  may  be  difficult.  Studies  reporting  a  direct
comparison of the histology features of PSVD and PVT are rare, mainly because the
patients  with  PVT  are  not  usually  submitted  to  liver  biopsy.  Moreover,  some
modifications  of  liver  histology,  such  as  nodular  regeneration  and  sinusoidal
dilatation, could be due to compensatory adaptation to the reduction of portal flow
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Table 1  Diseases associated to porto sinusoidal vascular liver disease
Thrombophilia
Myeloproliferative neoplasm
Protein S or C deficiency
Antiphospholipid antibodies
Lupus anticoagulant
Factor V Leiden
Prothrombin mutation
Hematologic disease
Myeloproliferative neoplasm (polycythemia vera, chronic myelogenous leukaemia, essential thrombocythemia)
Myeloid metaplasia
Lymphoproliferative conditions (Hodgkin’s disease, non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia and multiple myeloma)
Spherocytosis
Genetic disorders
Cystic fibrosis
Adams Oliver syndrome
Turner‘s disease
Autoimmune disease
Rheumatoid arthritis
Systemic lupus erythematosus
Systemic sclerosis
Scleroderma
Gut diseases
Celiac disease
Inflammatory bowel disease
Drug and toxics
Oxaliplatin
Azathioprine
6-thioguanine
Arsenic
Busulfan
Cytosine arabinoside
Cyclophosphamide
Bleomycin
Chlorambucil
Doxyrubicin
Carmustine
Acquired and congenital immunodeficiency
Human immunodeficiency virus
Primary antibody-deficiency syndrome
that is common to both conditions. Verheij et al[4] compared liver biopsies from 70
patients with PSVD and 23 patients with PVT and observed that phlebosclerosis (i.e.
obliterative portal venopathy), nodular regeneration and portal tract remnants (Figure
1A-C) were significantly more frequent in patients with PSVD than in those with PVT,
while portal  vein dilatation was more frequently observed in patients with PVT.
These results are in line with the hypothesis proposed by Wanless, which considers
PSVD  a  microvascular  disorder  resulting  from  injury  to  the  small  portal  vein
branches, whereas PVT is, by definition, a macrovascular disorder. However, the
applicability of the above described observations to the distinction of PVT secondary
or not to PSVD in the single patient is arguable. In fact, histological features, such as
sinusoidal dilatation, para-portal shunts and increased portal vessels, although with
different prevalence, are actually observed in both conditions. Moreover, the inclusion
of patients affected by a pre-existing PSVD in the PVT group in the study by Verheji et
al[4] cannot be completely ruled out. Consequently, due to this existing bias, it is hard
to really differentiate the first and the second group on the basis of histology.
Indeed, luminal narrowing and disappearance or sclerosis of the portal venous
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Figure 1
Figure 1  The three histologic features more frequent in porto sinusoidal vascular liver disease. A: Obliterative venopathy with small, rounded and fibrotic portal
tracts, without evidence of the portal vein branch; B: Portal tract remnant; C: Nodular regeneration (parenchymal micronodular transformation is indicated with an
asterisk).
radicles are typical changes observed in the fibrotic portal tract of PSVD patients[9].
Moreover, according to the endothelial-mesenchymal transition theory proposed by
Sato et al[10], which would explain in part the pathogenesis of the obliterative portal
venopathy, an endothelial dysfunction is present in patients with PSVD. The vascular
endothelial  cells  of  portal  venules  acquire  myofibroblastic  features  and start  to
synthesize type I collagen. Thus, as a consequence of the presence of a certain degree
of liver fibrosis in patients with PSVD, it can be hypothesised that the use of liver
stiffness  measurement  would be  helpful  to  distinguish patients  with  PSVD and
patients with PVT. The latter patients, at least theoretically, would be characterized by
a lower liver stiffness. A higher liver stiffness was actually observed in a group of 22
patients affected by regenerative nodular hyperplasia in comparison with 13 patients
with PVT[11,12].
In patients with PVT, especially if acute, the correct identification of a pre-existing
PSVD  as  the  condition  predisposing  to  PVT  has  relevant  practical  therapeutic
implications. In fact, even in the absence of consistent clinical studies, in patients with
PSVD, a lifelong anticoagulation is strongly suggested in presence of a prothrombotic
condition and/or a portal vein thrombosis[13]. On the contrary, current guidelines on
non-cirrhotic PVT do not suggest prolonging anticoagulation treatment lifelong in the
absence of a prothrombotic state and/or extension of the thrombosis to mesenteric
and splenic veins[13].  Thus, in a patient with PVT and an underlying undiagnosed
PSVD without a prothrombotic state and without extension of the thrombosis to
mesenteric and splenic veins, the anticoagulant therapy could be erroneously stopped
once the PVT is resolved. However, as in PSVD, the slowing down of the portal flow
is  probably  the  principal  condition  leading  to  PVT,  and  as  this  condition  is
irreversible, the stop of anticoagulation may induce the rapid relapse of PVT.
Figure 2 reports the computed tomography scan obtained in a 17-year-old male
patient  referred  to  our  ward  for  acute  portal  vein  thrombosis.  Because  of  the
negativity of any predisposing cause of portal vein thrombosis, including acquired
and congenital prothrombotic states, he was treated with oral anticoagulation for only
1 year, and complete portal vein recanalization was documented at the computed
tomography scan. However, after the withdrawal of anticoagulation, the patient had a
rapid relapse of PVT with the extension of the thrombosis to splenic vein. The patient
was  firstly  treated  with  low-molecular-weight-heparin  and  after  with  systemic
thrombolysis with alteplase reaching the complete resolution of the thrombosis. With
suspicion of porto sinusoidal vascular liver disease, the patient was submitted to liver
biopsy, and finally the diagnosis of PSVD was made by observing perivenular and
perisinusoidal  fibrosis,  sinusoidal  dilatation,  para-portal  shunts  and  nodular
regenerative hyperplasia.
In conclusion, PSVD is probably a not so rare condition that should be actively
searched  not  only  by  the  hepatologists  in  the  patients  with  signs  of  portal
hypertension but also by the specialists who manage the patients affected by diseases
associated with PSVD. Among the conditions associated with PSVD, PVT could be
also included, and the suspicion of a pre-existing and missed PSVD should arise in
any  patient  with  PVT  included  (and  maybe  especially)  in  those  affected  by  a
prothrombotic state.  However,  more studies are needed to clarify the distinctive
features of PSVD and PVT both histologically and elastographically, and new studies
are needed to clarify the indications and the benefits of anticoagulant therapy in
patients affected by PSVD.
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Table 2  Predisposing causes of portal vein thrombosis
Systemic prothrombotic conditions Recommended checks
Inherited Resistance to activated C protein/molecular biology for
  Factor V Leiden G1691A polymorphism
  Prothrombin gene mutation Molecular biology for G20210A polymorphism
  Protein C, protein S and antithrombin deficiency Ratio with F II, V, VII or X after correction for vitamin K deficiency; family survey (recommended)
Acquired
  Antiphospholipid syndrome Anticardiolipin ELISA; LLAC
  Myeloproliferative neoplasm (MPN) JAK2 and CALR mutations; osteomidullary biopsy
  Paroxysomal nocturnal hemoglobinuria Flow cytometry (deficient cells of CD55 and CD59)
  Oral contraceptive use Anamnesis
  Obesity BMI > 30 kg/m2
  CMV infection CMV IgG, CMV IgM
  Pregnancy Beta-HCG, anamnesis
  Celiac disease Anti-transglutaminase IgA/IgG
Local prothrombotic conditions Anamnesis and radiological examination
Surgery and trauma
  Umbilical cannulation
  Splenectomy, cholecystectomy
  Hepatic resection
  Abdominal trauma
  Bariatric surgery
  Portosystemic shunts including TIPS Anamnesis and radiological examination
Inflammatory and infectious diseases
  Neonatal omphalitis
  Appendicitis, diverticulitis, pancreatitis
  Inflammatory bowel disease
  Cholecystitis, cholangitis
Other
  Cirrhosis
  Porto sinusoidal vascular liver disease
LLAC: Lupus-like anticoagulant; ELISA: Enzyme-linked immunosorbent assay; BMI: Body mass index; CMV, Cytomegalovirus; HCG: Human chorionic
gonadotropin; Ig: Immunoglobulin; TIPS: Transjugular portosystemic intrahepatic shunt.
Figure 2
Figure 2  Contrast-enhanced computed tomography scan of a 17 year-old patient. A: Occlusive thrombosis of the trunk of portal vein; B: Complete resolution of
the portal vein thrombosis after 1 year of anticoagulant therapy; C: Relapse of the portal vein thrombosis with extension to splenic vein 1 months after the stop of the
anticoagulant therapy.
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